Drug intelligence / Profile preview

KY1107

Development stage: Preclinical
Lead developer: KYDES Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

KY1107 is an investigational abuse-deterrent oral formulation (ADF) of an opioid analgesic being developed by KYDES Pharmaceuticals for the management of severe pain. The formulation is designed with abuse-deterrent properties to mitigate common methods of prescription drug misuse, such as crushing or dissolving for non-oral administration. KY1107 exerts its therapeutic effect by acting as an agonist at opioid receptors in the central nervous system. It is currently in the preclinical stage of development.

Targets

DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on KY1107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KY1107.

Explore the full profile